What is Pulmonx Corp Annual Revenue?

Pulmonx Corp Annual Revenue rose 22.01%, in the last year to $83.79 M. Its sector's average revenue growth for the last fiscal year was 8.57%.

What is Pulmonx Corp Annual Net Profit?

Pulmonx Corp Annual Net Profit rose 7.31% in the last year to $56.39 M. Its sector's average net profit growth for the last fiscal year was 4.36%.

What is Pulmonx Corp Price to Earning Ratio?

Pulmonx Corp Price to Earning Ratio is -3.23, which is negative.

What is Pulmonx Corp Stock Price?

Pulmonx Corp Stock Price fell 39.81% and underperformed its sector by 45.24% in the past year.

What is Pulmonx Corp Quarterly Revenue?

Pulmonx Corp Quarterly Revenue rose 23.28% YoY to $23.76 M. Its sector's average revenue growth YoY for the quarter was 8.5%.

What is Pulmonx Corp Quarterly Net profit?

Pulmonx Corp Quarterly Net profit rose 5.13% YoY to $13.18 M. Its sector's average net profit growth YoY for the quarter was 32.89%.

What is Pulmonx Corp Debt to Equity Ratio?

Pulmonx Corp Debt to Equity Ratio of 0.66 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

What is Pulmonx Corp Return on Equity(ROE)?

Pulmonx Corp Return on Equity(ROE) for the last financial year was -55.25%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

What is Pulmonx Corp Mutual Fund Holding?

Pulmonx Corp Mutual Fund Holding increased by 0.21% in the last quarter to 61.37.

What is Pulmonx Corp Interest Coverage Ratio?

Pulmonx Corp Interest Coverage Ratio is -14.94, lesser than one. This means that it is unable to pay interests with its earnings (EBIT).

What is Pulmonx Corp Institutional Holding?

Pulmonx Corp Institutional Holding increased by 0.01% in the last quarter to 94.3.

How is the Pulmonx Corp today?

The Pulmonx Corp today is trading in the down by -5.64% at 4.52.

How has Pulmonx Corp performed historically?

The Pulmonx Corp is currently trading down -5.64% on an intraday basis in the past week the index fell -13.90%. The index has been down -27.80% in the past quarter and fell -39.81% in the past year. You can view this in the overview section.

Pulmonx Corp XNAS: LUNG

Pulmonx Corp Live Share Price Today, Share Analysis and Chart

Name: Pulmonx Corp: Is Infosys Ltd. worth buying?
Item: Pulmonx Corp
Rating: 1.013708375
Author: Trendlyne DVM scores

Weak Stock

Download real time

4.52 -0.27 (-5.64%)

New 52W Low today

355.3K XNAS Volume

XNAS 17 Apr, 2025 5:30 PM (EDT)

Board Meeting

The next board meeting for Pulmonx Corp is on 01 May 2025 for the purpose of Pulmonx Corp First Quarter Earnings Results for 2025 See details

Pulmonx Corp Key Metrics

My Metrics

Select

Market Capitalization Below industry Median Unavailable in chosen country	181.9
PE TTM Negative PE TTM Unavailable in chosen country	-3.2
PEG TTM Negative PEG TTM Unavailable in chosen country	-0.4
Price to Book Below industry Median Unavailable in chosen country	2.1
Institutional holding current Qtr % High in industry Unavailable in chosen country	94.3
Revenue Growth Qtr YoY % Below industry Median Unavailable in chosen country	23.3
Operating Revenue growth TTM % Below industry Median Unavailable in chosen country	22
Net Profit Qtr Growth YoY % Below industry Median Unavailable in chosen country	5.1
Net Profit TTM Growth % Below industry Median Unavailable in chosen country	7.3
Operating Profit Margin Qtr % Negative Operating Profit Margin Qtr % Unavailable in chosen country	-56.5
Operating Profit Margin TTM % Negative Operating Profit Margin TTM % Unavailable in chosen country	-68.9
Piotroski Score Below industry Median Unavailable in chosen country	2
Rel Perf vs Sector quarter% Unavailable in chosen country	-20.5
ROE Annual % Negative ROE Annual % Unavailable in chosen country	-55.3
RoA Annual % Negative RoA Annual % Unavailable in chosen country	-33.1

All financials are in USD Million and price data in USD

Low Financial Strength

16.7 / 100

Expensive Valuation

18.3 / 100

Technically Bearish

29.4 / 100

Weak Stock These stocks are the ones with poor quality, financials and technicals. This indicates that investors should be highly watchful with these stocks. View Similar Embed DVM

1Yr Price target upside is 173%

7 analysts

Check Before You Buy

Check P/E Buy Sell Zone

This stock has negative PE

Pulmonx Corp Stock Price Analysis

Day Price Range -5.6% 1 Day return Unavailable in chosen country	4.5 (LTP) 4.54.9 LowHigh
Week Price Range -13.9% 1 Week return Unavailable in chosen country	4.5 (LTP) 4.55.5 LowHigh
Month Price Range -41.3% 1 Month return Unavailable in chosen country	4.5 (LTP) 4.58 LowHigh
52 Week Price Range -39.8% 1 Year return Unavailable in chosen country	4.5 (LTP) 4.510 LowHigh

View full Share Price History

Pulmonx Corp Live Price Chart

Switch to TradingView

Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Hit

Pulmonx Corp's Revenue was higher than average estimate 3 times in past 3 years

EPS forecast

QUARTER
ANNUAL

Current EPS

-1.4

Avg. Estimate

-1.5

Low Estimate

-1.6

High Estimate

-1.5

Current EPS

Avg. Estimate

Consensus Recommendation

7 ANALYST Recommendations

BUY

The consensus recommendation from 7 analysts for Pulmonx Corp is BUY

Forecaster is a Premium Feature

You need to upgrade your subscription plan to access this feature

Upgrade Now

Pulmonx Corp Stock Analysis

Pulmonx Corp stock analysis with key metrics, changes, and trends.

Pulmonx Corp Metric	VALUE	CHANGE %	TREND	ANALYSIS
Annual Revenue	$83.79 M	22.01%	positive	Annual Revenue rose 22.01%, in the last year to $83.79 M. Its sector's average revenue growth for the last fiscal year was 8.57%.
Annual Net Profit	$56.39 M	7.31%	positive	Annual Net Profit rose 7.31% in the last year to $56.39 M. Its sector's average net profit growth for the last fiscal year was 4.36%.
Price to Earning Ratio	-3.23	-	negative	Price to Earning Ratio is -3.23, which is negative.
Stock Price	$4.52	-39.81%	negative	Stock Price fell 39.81% and underperformed its sector by 45.24% in the past year.
Quarterly Revenue	$23.76 M	23.28%	positive	Quarterly Revenue rose 23.28% YoY to $23.76 M. Its sector's average revenue growth YoY for the quarter was 8.5%.
Quarterly Net profit	$13.18 M	5.13%	positive	Quarterly Net profit rose 5.13% YoY to $13.18 M. Its sector's average net profit growth YoY for the quarter was 32.89%.
Debt to Equity Ratio	0.66	-	positive	Debt to Equity Ratio of 0.66 is less than 1 and healthy. This implies that its assets are financed mainly through equity.
Return on Equity(ROE)	-55.25 %	-55.25%	negative	Return on Equity(ROE) for the last financial year was -55.25%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.
Mutual Fund Holding	61.37 %	0.21%	positive	Mutual Fund Holding increased by 0.21% in the last quarter to 61.37.
Interest Coverage Ratio	-14.94	-	negative	Interest Coverage Ratio is -14.94, lesser than one. This means that it is unable to pay interests with its earnings (EBIT).
Institutional Holding	94.30 %	0.01%	positive	Institutional Holding increased by 0.01% in the last quarter to 94.3.

VIEW LESS

Loading data..

Pulmonx Corp - Company Profile

What does Pulmonx Corp do?

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

Year

Mr. Geoffrey Beran Rose

Chief Commercial Officer

2024

154.99 K

2024

Gross Remuneration

Year

Pulmonx Corp Live Share Price Today, Share Analysis and Chart

New 52W Low today

Pulmonx Corp Key Metrics

Market Capitalization

PE TTM

PEG TTM

Price to Book

Institutional holding current Qtr %

Revenue Growth Qtr YoY %

Operating Revenue growth TTM %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Operating Profit Margin Qtr %

Operating Profit Margin TTM %

Piotroski Score

Rel Perf vs Sector quarter%

ROE Annual %

RoA Annual %

SWOT Analysis

Check Before You Buy

Check P/E Buy Sell Zone

Pulmonx Corp Stock Price Analysis

Day Price Range

Week Price Range

Month Price Range

52 Week Price Range

Pulmonx Corp Live Price Chart

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Pulmonx Corp's Revenue was higher than average estimate 3 times in past 3 years

EPS forecast

Consensus Recommendation

The consensus recommendation from 7 analysts for Pulmonx Corp is BUY

Pulmonx Corp Stock Analysis

Pulmonx Corp stock analysis with key metrics, changes, and trends.

Annual Revenue rose 22.01%, in the last year to $83.79 M. Its sector's average revenue growth for the last fiscal year was 8.57%.

Annual Net Profit rose 7.31% in the last year to $56.39 M. Its sector's average net profit growth for the last fiscal year was 4.36%.

Price to Earning Ratio is -3.23, which is negative.

Stock Price fell 39.81% and underperformed its sector by 45.24% in the past year.

Quarterly Revenue rose 23.28% YoY to $23.76 M. Its sector's average revenue growth YoY for the quarter was 8.5%.

Quarterly Net profit rose 5.13% YoY to $13.18 M. Its sector's average net profit growth YoY for the quarter was 32.89%.

Debt to Equity Ratio of 0.66 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

Return on Equity(ROE) for the last financial year was -55.25%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

Mutual Fund Holding increased by 0.21% in the last quarter to 61.37.

Interest Coverage Ratio is -14.94, lesser than one. This means that it is unable to pay interests with its earnings (EBIT).

Institutional Holding increased by 0.01% in the last quarter to 94.3.

Pulmonx Corp - Company Profile

What does Pulmonx Corp do?

Pulmonx Corp Management structure

Mr. Steven S. Williamson

Director, President and Chief Executive Officer

Mr. Mehul Joshi

Chief Financial Officer and Principal Accounting Officer

Mr. David A. Lehman

General Counsel

Mr. Glendon E. French

Director, President and Chief Executive Officer

Mr. John McKune

Vice President, Finance and Corporate Controller

Mr. Geoffrey Beran Rose

Chief Commercial Officer

Pulmonx Corp Board of directors

Mr. Dana G. Mead, Jr

Non-Executive Chairman of the Board

Mr. Daniel P. Florin

Independent Director

Ms. Georgia Garinois-Melenikiotou

Independent Director

Mr. Richard M. Ferrari

Independent Director

Mr. Thomas W. Burns

Independent Director

Ms. Tiffany Sullivan

Independent Director

Pulmonx Corp FAQ

How is Pulmonx Corp today?

Pulmonx Corp today is trading in the red, and is down by -5.64% at 4.52.

How has Pulmonx Corp performed historically?

Pulmonx Corp is currently trading down -5.64% on an intraday basis. In the past week the stock fell -13.90%. stock has been down -27.80% in the past quarter and fell -39.81% in the past year. You can view this in the overview section.